Obstinate thrombosis during percutaneous coronary intervention in a case with heparin-induced thrombocytopenia with thrombosis syndrome successfully treated by argatroban anticoagulant therapy

Catheterization and Cardiovascular Interventions

Volumn 59, Issue 3, 2003, Pages 351-354

  Sakai, Katsuyuki ^a   Oda, Hirotaka ^a   Honsako, Akihiro ^a   Takahashi, Kazuyoshi ^a   Miida, Tutomu ^a   Higuma, Norio ^a  

^a NIIGATA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Argatroban; Coronary stent; Heparin induced thrombocytopenia with thrombosis syndrome

Indexed keywords

ARGATROBAN; HEPARIN;

ADULT; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CORONARY ARTERY THROMBOSIS; CORONARY STENT; HEART CATHETERIZATION; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY STENOSIS; CORONARY THROMBOSIS; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PIPECOLIC ACIDS; RISK ASSESSMENT; SYNDROME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037678467     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10536     Document Type: Article

References (12)

1. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Tegh M, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
2. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507.
3. Amiral J, Bridey, F, Dreyfus M, Vissac AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-96.
4. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-88.
5. Warkentin TE, Kelton JG. Temporal aspect of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-1292.
6. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial cell injury in heparin induced-associated thrombocytopenia. N Engl J Med 1987;316:581-589.
7. Makhoul RG, Greeberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. J Vasc Surg 1986;4:522-528.
8. Manfredi JA, Wall RP, Sane DC, Braden GA. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case reports. Cathet Cardiovasc Intervent 2001;52:468-472.
9. Lewis BE, Wallis DE, Bercowitz SD, Matthai WH, Fareed J, Walega JM, Barthrolomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG. Argatroban anticoagulant therapy in patients with heparininduced thrombocytopenia. Circulation 2001;103:1838-1843.
10. Lewis BE, Ferguson JJ, Grassman ED, Fareed J, Walenga J, Joffrion JL, Wrona L, Johnson SA, Schwarz RP, McKiernan T. Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invas Cardiol 1996;8:410-417.
11. Lewis BE, Iaffaldano R, McKierman TL, Rao L, Donkin J, Wallenga J. Report of successful use of argatroban as a alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Cathet Cardiovasc Diagn 1996;38:206-209.
12. Matthai WH. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thrombo Hemosta 1999;25(Suppl 2):57-60.